Business
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level Productive Type C Meeting Held With FDA; Registrational Development of Cemsidomide in Multiple Myeloma on Track to Initiate in Early 2026 Preclinical Milestone Achieved Under the Collaboration With Merck KGaA, Darmstadt, Germany, Which Is
About this update from Merck Kgaa
[{"type":"image","alt":"C4 Therapeutics, Inc.","displaySize":"","headline":null,"caption":"C4 Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":45,"url":"https://media.zenfs.com/en/globenewswire.com/bde91dc9d9165d239ff6e430c73a2d85"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/octIZ3xbuMh0O2fgF.yqVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/bde91dc9d9165d239ff6e430c73a2d85","width":300,"height":45}},"lazy":false},{"type":"text","content":"Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level","length":267,"tagName":"p"},{"type":"text","content":"Productive Type C Meeting Held With FDA; Registrational Development of Cemsidomide in Multiple Myeloma on Track to Initiate in Early 2026","length":137,"tagName":"p"},{"type":"text","content":"Preclinical Milestone Achieved Under the Collaboration With Merck KGaA, Darmstadt, Germany, Which Is Focused on Two Projects Within the KRAS Family ","length":147,"tagName":"p"},{"type":"text","content":"Disciplined Capital Allocation Extends Runway to Mid-2027","length":57,"tagName":"p"},{"type":"text","content":"WATERTOWN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the second quarter ended June 30, 2025, as well as business updates.","length":305,"tagName":"p"},{"type":"text","content":"“The first half of 2025 was driven by focused execution across our business with the achievement of several research milestones with our collaborators and within our internal preclinical pipeline, the advancement of cemsidomide toward label-enabling trials and continued financial discipline that resulted in extending cash runway. We recently completed enrollment in the ongoing cemsidomide Phase 1 trials in multiple myeloma and non-Hodgkin’s lymphoma and look forward to sharing the full Phase 1 multiple myeloma data in September, which we believe further demonstrate cemsidomide’s best-in-class potential. Our recent Typ...